Metabolically-targeted dCas9 expression in bacteria

被引:3
|
作者
Pellegrino, Gregory M. [1 ]
Browne, Tyler S. [1 ]
Sharath, Keerthana [1 ]
Bari, Khaleda A. [1 ]
Vancuren, Sarah J. [2 ]
Allen-Vercoe, Emma [2 ]
Gloor, Gregory B. [1 ]
Edgell, David R. [1 ]
机构
[1] Schulich Sch Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada
[2] Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada
基金
加拿大健康研究院;
关键词
ESCHERICHIA-COLI K-12; BETA-GLUCURONIDASE; GENE-EXPRESSION; HEXURONATE METABOLISM; MICROBIAL CONSORTIA; GUT MICROBIOTA; TRANSCRIPTION; SEQUENCE; CRISPR; MUTANTS;
D O I
10.1093/nar/gkac1248
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ability to restrict gene expression to a relevant bacterial species in a complex microbiome is an unsolved problem. In the context of the human microbiome, one desirable target metabolic activity are glucuronide-utilization enzymes (GUS) that are implicated in the toxic re-activation of glucuronidated compounds in the human gastrointestinal (GI) tract, including the chemotherapeutic drug irinotecan. Here, we take advantage of the variable distribution of GUS enzymes in bacteria as a means to distinguish between bacteria with GUS activity, and re-purpose the glucuronide-responsive GusR transcription factor as a biosensor to regulate dCas9 expression in response to glucuronide inducers. We fused the Escherichia coli gusA regulatory region to the dCas9 gene to create pGreg-dCas9, and showed that dCas9 expression is induced by glucuronides, but not other carbon sources. When conjugated from E. coli to Gammaproteobacteria derived from human stool, dCas9 expression from pGreg-dCas9 was restricted to GUS-positive bacteria. dCas9-sgRNAs targeted to gusA specifically down-regulated gus operon transcription in Gammaproteobacteria, with a resulting similar to 100-fold decrease in GusA activity. Our data outline a general strategy to re-purpose bacterial transcription factors responsive to exogenous metabolites for precise ligand-dependent expression of genetic tools such as dCas9 in diverse bacterial species.
引用
收藏
页码:982 / 996
页数:15
相关论文
共 50 条
  • [1] Gene silencing with CRISPRi in bacteria and optimization of dCas9 expression levels
    Depardieu, Florence
    Bikard, David
    METHODS, 2020, 172 : 61 - 75
  • [2] Harnessing targeted DNA methylation and demethylation using dCas9
    Pflueger, Christian
    Swain, Tessa
    Lister, Ryan
    DNA METHYLATION, 2019, 63 (06): : 813 - 825
  • [3] Characterizing enhancers with dCas9
    Zlotorynski, Eytan
    NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2015, 16 (05) : 266 - 267
  • [4] Characterizing enhancers with dCas9
    Eytan Zlotorynski
    Nature Reviews Molecular Cell Biology, 2015, 16 (5) : 267 - 267
  • [5] Epigenetic control of heparanase expression through CRISPR/dCas9
    Zeng, Guihua
    Liang, Fu-Sen
    Cui, Lina
    CANCER RESEARCH, 2019, 79 (13)
  • [6] Crispr/dCas9 and gene activation
    Akinci, Ersin
    Unal, Pelin
    Badakul, Gamze
    Yildiz, Mehmet
    JOURNAL OF BIOTECHNOLOGY, 2017, 256 : S42 - S42
  • [7] RNA polymerase collisions with dCas9
    Agapov, A.
    Esyunina, D.
    Kulbachinskiy, A.
    FEBS OPEN BIO, 2021, 11 : 238 - 238
  • [8] Engineered dCas9 with reduced toxicity in bacteria: implications for genetic circuit design
    Zhang, Shuyi
    Voigt, Christopher A.
    NUCLEIC ACIDS RESEARCH, 2018, 46 (20) : 11115 - 11125
  • [9] Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System
    Moses, Colette
    Nugent, Fiona
    Waryah, Charlene Babra
    Garcia-Bloj, Benjamin
    Harvey, Alan R.
    Blancafort, Pilar
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2019, 14 : 287 - 300
  • [10] Split dCas9 AAV for Knockdown of HTT
    Waldo, Jennifer
    Halmai, Julian
    Onate, Tracy
    Yang, Sheng
    Cameron, David
    Villegas, Isaac
    Buchanan, Fiona
    Nolta, Jan
    Fink, Kyle
    MOLECULAR THERAPY, 2022, 30 (04) : 446 - 446